Clinical Trial Update: Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia [Phase 1]

View source ↗

Summary

Clinical trial update for an allogeneic CD7 CAR γδ T cell therapy in recurrent/refractory leukemia; Phase 1 currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Allogeneic CD7 CAR γδ T Cells Therapy

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Leukemia | Phase 1 | Status: NOT_YET_RECRUITING